After a median follow-up of @ months ( IQR @-@ ) , overall survival was significantly improved for patients with adenocarcinoma histology who progressed within @ months after start of first-line treatment in the docetaxel plus nintedanib group ( @ patients ) compared with those in the docetaxel plus placebo group ( @ patients ; median @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @-@ -RSB- ; HR @ -LSB- @ % CI @-@ -RSB- , p = @ ) .